1. Moving Care Forward in Advanced Gastric Cancer

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Immune Checkpoint Inhibition

5. ICIs Approved for G/GEJ Cancers

6. MSI-H/dMMR Tumors

7. MSI-H/dMMR in Second-Line Setting Pembrolizumab

8. MSI-H/dMMR in Second-Line Setting Nivolumab

9. What Does PD-L1 Positive Mean?

10. Pembrolizumab for PD-L1-Positive in Third-Line Setting KEYNOTE-059

11. Nivolumab for PD-L1-Positive in Third-Line Setting ATTRACTION-2

12. Practical Implications -- Deciding Who to Treat

13. Other Biomarkers

14. Immune-Related Adverse Events

15. Practical Implications Managing irAEs

16. Pembrolizumab in G/GEJ -- Negative Trial KEYNOTE-061

17. Avelumab in G/GEJ -- Negative Trial Javelin Gastric 300

18. Pembrolizumab for Esophageal Cancer in Third-Line KEYNOTE-180

19. Pembrolizumab for Esophageal Cancer in Second-Line KEYNOTE-181

20. Implications of Results

21. Immunotherapy Plus Chemotherapy First-Line Setting

22. Future Phase 3 Trials First-Line Setting

23. Future Phase 3 Trials First-Line Setting (cont)

24. Future Trials The Adjuvant and Neoadjuvant Settings

25. Future Trials The Adjuvant and Neoadjuvant Settings (cont)

26. IO-IO Combination Therapy CheckMate-032

27. Ongoing Research Combination IO-IO

28. Ongoing Research Immunotherapy With VEGFR2 Inhibitor

29. Ongoing Research Immunotherapy With HER2 Inhibitors

30. Key Takeaways

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)